NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Sponsors and Collaborators
Robert Medve, MD
Charleen Jue, B.S.
Next post in Colorectal Cancer Clinical Trials
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
Want to read more?
Please login or register first to view this content.